Revive Therapeutics Ltd

Revive Therapeutics has a negative equity position of CAD -3,455,700 and a current ratio of 0.02, indicating severe liquidity constraints. The company's cash and equivalents amount to CAD 14,560, while its total liabilities exceed total assets by CAD 3,455,700. The negative return on assets of -53.71% highlights the company's inability to generate returns from its asset base. The company's profitability is weak, with a net loss of CAD 11,011,320 and an operating loss of CAD 10,956,370. The return on equity of 3.19% is misleading due to the negative equity base, and the debt-to-equity ratio of -0.02 suggests minimal leverage but also reflects the company's negative net worth. Revive Therapeutics does not disclose segment or geographic revenue breakdowns in the provided data, making it difficult to assess revenue concentration or geographic exposure. The company's operations are likely centered in North America, but this is inferred rather than stated. The company's growth trajectory is uncertain, with no revenue growth data provided. The operating cash flow of CAD -767,660 and free cash flow of CAD -11,011,070 indicate ongoing cash burn. The company is not generating positive cash flows from operations, which is a concern for long-term sustainability. The risk assessment indicates medium liquidity risk and low dilution risk. The company's negative net cash position after subtracting total debt is a key flag. The dilution risk is low, but the company's negative equity and cash flow position suggest a high risk of further dilution if it needs to raise additional capital. Recent events include the company's continued financial losses and negative cash flows, as disclosed in the latest financial statements. No specific recent filings or transcripts are provided in the data, but the ongoing financial performance suggests the company is in a challenging position.